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ABSTRACT:  The French National Authority for Health (Haute Autorité de Santé, or HAS) 
was established to assist France’s public institutions in optimizing the basket of reimburs-
able goods and services and to help health care professionals continuously improve their 
clinical practice by defining best-care standards and identifying relevant tools and meth-
ods. HAS carries out single technology assessment (STA) and multiple technology assess-
ment (MTA), assessing both the intrinsic benefit of the new technology and its effective-
ness compared with that of existing technologies. A new treatment may not be covered 
unless it provides either improved benefit or lower cost, and STA is mandatory before a 
new drug, device, or medical procedure can be added to the benefit list for sickness funds. 
While HAS recommendations are advisory, the decision-making bodies (the Ministry of 
Health or the union of sickness funds) accept its findings in most cases.
                    
OVERVIEW
The French National Authority for Health (Haute Autorité de Santé, or HAS) was 
created by the National Health Insurance Reform Act of 2004 and was estab-
lished on January 1, 2005. HAS was established to assist decision-making by 
public institutions, with the goals of optimizing the basket of reimbursable goods 
and services and helping health care professionals continuously improve their 
clinical practice by defining best-care standards and identifying relevant tools 
and methods. It is an independent, scientific, public authority that has financial 
autonomy and a unique legal identity. 
HAS brings together within a single entity a number of functions designed 
to improve the quality of patient care and to guarantee equity within the health 
care system. HAS’s activities are diverse and range from assessment of drugs, 
medical devices, and procedures to publication of guidelines, accreditation of 
health care organizations, and certification of doctors. As part of that overall mis-
sion, HAS provides health authorities with the information needed to make deci-
sions on the reimbursement of medical products and services, including assess-
ment of drugs, medical devices, and diagnostic and therapeutic procedures that 
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are covered by National Health Insurance (NHI). HAS 
is not a government body. It is an independent public 
organization with financial autonomy and a Board 
appointed by government officials. HAS is mandated 
by law to carry out its mission and reports to 
Government and Parliament. It liaises closely with 
government health agencies, national health insurance 
funds, research organizations, unions representing 
health care professionals, and patients’ representa-
tives.1 It has dedicated funding sources, most impor-
tantly a tax on pharmaceutical companies’ advertising 
expenditures. This paper focuses on HAS’s health 
technology assessment activities.
HAS carries out two kinds of health technology 
assessment (HTA): single technology assessment 
(STA) and multiple technology assessment (MTA). 
STA is initiated at the request of a drug or device man-
ufacturer or a professional society for medical proce-
dures. STA is mandatory before a new drug, device, or 
medical procedure can be added to the benefit list for 
sickness funds and is used for pricing decisions. HAS 
assesses both the intrinsic benefit of the new technol-
ogy and its effectiveness compared with that of exist-
ing technologies. A new treatment may not be covered 
unless it provides either improved benefit or lower 
cost. While HAS recommendations are advisory, the 
decision-making bodies (the Ministry of Health or the 
union of sickness funds) accept its findings in most 
cases. STAs are produced rapidly—within an average 
of 73 days for new drugs.
MTA reviews an entire class of drugs, devices, 
or procedures. Recent examples include a review of 
Alzheimer’s drugs and a report on strategy for the 
management of carotid stenosis. MTAs can also take 
the form of guidelines on public health interventions 
(screening) or issues in the organization of care. MTA 
projects may be initiated by HAS, but usually stem 
from requests from public agencies or other interested 
parties. The scope of the assessment and appropriate 
methods are developed in consultation 
1 “Haute Autorité de santé (HAS): About Us”, 
http://www.has-sante.fr/portail/jcms/c_5443/
english?cid=c_5443, accessed on June 3, 2009.
with stakeholders; in addition to clinical benefits, 
assessments may address economical, ethical, and 
legal aspects of the study topic.
Legislation in 2008 gave HAS the new mission 
of conducting economic assessments. These include 
cost-effectiveness comparisons of specific products, as 
well as more global studies of the value to the commu-
nity of different health strategies and technologies. 
Economic evaluations will generally be part of MTA, 
rather than STA, projects. To conduct these studies, 
HAS has established a new department with an inde-
pendent oversight committee.
PRINCIPLES AND VALUES
The approach taken by HAS can be characterized as:
Integrated.•	  HAS takes a global approach to dis-
ease management and quality in health care, 
covering a large number of fields, including 
technology assessments, clinical guidelines, 
hospital certification, quality improvement ini-
tiatives in health care at both macro (hospitals, 
networks) and micro (heath professionals, 
patients) levels, external evaluations of organi-
zations, and development of public health strat-
egies such as screening policies;
Scientific.•	  As a scientific body, HAS must use 
the principles of evidence-based medicine and 
ensure that its products are developed with 
methodological robustness and rigor. This 
requires the use of appropriate and up-to-date 
expertise in all fields of evaluation;
Transparent.•	  Both the methods used and the 
advice given are made publicly available;
Inclusive.•	  HAS strives to include all stakehold-
ers (professionals, patient representatives, deci-
sion-makers, medical technology manufactur-
ers) at various stages in the production of 
advice, opinions, and guidelines;
Impact-based.•	  HAS must assess the relevance 
and impact of its decisions and advice in terms 
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assigned to HAS by law and for developing its strat-
egy. The Board is composed of eight members, 
appointed for six year terms, renewable one time. Two 
members are proposed by each of the following: the 
President of the Republic, the Speaker of the Senate, 
the Speaker of the National Assembly and the Chair of 
the Economic and Social Council. Seven specialist 
committees, each chaired by a board member, are 
responsible for examining proposed findings prepared 
by the HAS operational departments.
In 2008, the HAS operating budget was € 71.7 
million; actual spending was € 66 million. Although 
HAS is a public entity, it has its own revolving fund, 
and most revenues do not come directly from the gov-
ernment. The largest income sources are proceeds 
from a tax on pharmaceutical companies’ advertising 
spending and funding from the health insurance fund.
In 2007, HAS committees issued over 1,200 
assessments of specific health treatments, including:
940 opinions about drugs (267 for a first listing, •	
41 for a new indication, the remainder dealing 
mainly with renewals);
236 opinions about devices and health •	
technologies; and
83 opinions about medical and surgical •	
procedures.
It also issued a number of multiple technology 
assessments, economic assessments, and public health 
guidelines.
of professionals’ behavior as well as medical 
outcomes, when possible;
Independent.•	  HAS’s products, whether devel-
oped internally or externally, are reviewed by 
independent scientific specialist committees 
whose members are drawn from clinicians, pro-
fessional groups, researchers, and patient and 
public representatives. HAS is independent 
from government or from other bodies request-
ing advice;
Up-to-date.•	  All HAS products are updated at 
regular intervals (three to four years, or earlier 
if new evidence becomes available); and
Timely.•	  Timeliness is increasingly important for 
HAS and new methods are currently being 
developed for rapid responses.
STRUCTURE, SIZE, AND OUTPUTS
HAS employs approximately 400 full-time staff, of 
whom about 80 are dedicated to health technology 
assessment. In addition to its full-time staff, HAS 
works with 34 regional project leaders (who are 
involved in assessment activities), 734 surveyors, and 
over 3,000 external consultant experts and health care 
practitioners.
The HAS Board is the organization’s delibera-
tive body and is accountable for the rigor and impar-
tiality of HAS’s output. It is responsible for program-
ming, steering, and implementing the missions 
Table 1. Sources of HAS Income, 2008
10% of proceeds from the tax on pharmaceutical company spending on advertising 47%
Fees from manufacturers 8%
Contribution from the health insurance fund 33.5%
Government subsidy 6%
Miscellaneous (investment income) 4%
Source: HAS 2008 annual report.
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USING COMPARATIVE EFFECTIVENESS 
RESEARCH TO INFORM POLICY DECISIONS
Health technology assessment activities at HAS deal 
with public health interventions, drugs, medical 
devices, and medical and surgical procedures. 
Increasingly, HAS strives to enlarge its appraisals, 
beyond clinical effectiveness, by including, when 
judged relevant, economic, societal, ethical, organiza-
tional, and judicial dimensions.
HAS carries out two kinds of health technology 
assessment (HTA) activity: single technology assess-
ment, focusing one drug or other treatment, and multi-
ple technology assessment, which reviews an entire 
class of drugs or devices. Single technology assess-
ments account for about 80 percent of drug assessment 
activity, 20 percent of medical device assessments, and 
50 percent of procedure assessments.
Single Technology Assessment (STA)
HAS assessment is mandatory before inclusion of any 
new health technology on the health insurance benefit 
list. This applies to drugs, devices, equipment, biologi-
cal tests, and medical and surgical procedures. Based 
on the assessment, HAS gives an “opinion” on the 
expected or actual	benefit provided by the technology, 
as well as on the	improvement	in	expected	benefit 
(assessment of relative/comparative effectiveness) in 
regard to a standard comparator (comparative effec-
tiveness). The opinions issued by HAS support cover-
age and reimbursement decisions, as well as decisions 
on the pricing of both health products and procedures. 
Its assessment may also be required for modifications 
to coverage conditions, such as new indications for 
technologies already listed.
HAS opinions on pharmaceutical products and 
medical devices are forwarded to the Ministry for 
Health and Social Security. Based on HAS conclu-
sions, the Minister decides whether or not to reimburse 
the products, and the committee in charge of setting 
prices at the Ministry negotiates a price/volume con-
tract with the manufacturer. The current regulatory 
requirement is that “medicines that neither provide a 
therapeutic added value (as assessed by HAS) nor cost 
savings” may not be included in the list of reimbursed 
products. As a consequence, products for which HAS 
recognizes no added value can only be reimbursed if 
they are less costly than comparators. The pricing 
committee may grant a higher price than comparators 
for drugs that produce an improvement in actual benefit.
For procedures and biological tests, coverage 
and pricing decisions also reflect HAS advice, but are 
made by the national sickness funds union, which  
represents the three largest health insurance funds—
CPAM, the mandatory fund for salaried employees, 
and the separate funds for the self-employed and  
for farmers.
Depending on the type of technology, a reas-
sessment may be planned at regular intervals (every 
five years for drugs, within five years for medical 
devices, and variable for procedures) for renewal of 
coverage decision.
Multiple Technology Assessment (MTA)
HAS produces assessments of therapeutic classes of 
drugs or categories of medical devices/equipment. It 
also produces public health intervention assessments 
and reports on issues related to the organizational 
dimensions of the health system. In general, MTAs 
clarify strategic choices, allow redefinition of condi-
tions of use, and support a more global approach to 
structural decisions regarding coverage policy, health 
care delivery, or health care organization.
The following list gives examples of MTA proj-
ects recently conducted by HAS (all reports are avail-
able on the HAS Web site):
Alzheimer’s drugs review•	
Medical devices: total hip prostheses, wound •	
dressings, self-monitoring glycemia devices, 
cochlear implants, implants for wall repair in 
genito-urology and digestive surgery, cardiac 
pacemakers
Third-generation oral contraceptives•	
Strategy for the management of carotid stenosis: •	
indications for revascularization techniques
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Cardiac surgery with or without extra-corporeal •	
circulation: role of the second surgeon
Dental prostheses with a ceramic structure•	





STA activity is determined by applications submitted 
by the pharmaceutical or medical device industry or, in 
the case of procedure assessments, by professional 
associations. All new drugs and devices and all new 
indications for existing treatments are submitted to 
HAS before inclusion on the reimbursement list. 
Unlike STA activity, MTA activity is planned on a 
yearly basis, following a work program definition pro-
cess. This process includes several steps: customers’ 
solicitation, selection criteria definition, proposal and 
validation by internal decision bodies, definition of 
reporting modalities of the final program content, as 
well as implementation follow-up. Although HAS has 
the right to self-select topics, most of the MTA work 
program is based on requests by public institutions 
(sickness funds, general directorates at the Ministry for 
Health and Social Security), academic societies, and 
patients’ associations.
This work program is now defined simultane-
ously and in coherence with other HAS activities, such 
as accreditation. The global objective is to create the 
best interaction possible between HTA activities and 
the guidelines and evaluation systems applied to health 
professionals’ practices or health care organizations.
Methods
For STA, assessment is based on evidence from compa-
nies, when relevant, literature reviews, and other relevant 
data sources. Internal assessments, focusing on clinical 
effectiveness, target population definition, and condi-
tions of use for already reimbursed technologies are val-
idated by external clinical or methodological experts.
An opinion is then given by one of the special-
ized committees, focusing on two criteria: 
The •	 intrinsic	value of the drug, device, or pro-
cedure, based on effectiveness assessment. The 
actual benefit represents the combined assess-
ment of the severity of the medical condition 
treated, the efficacy/safety ratio (clinical 
impact), the expected positioning of the product 
within the existing therapeutic strategy, and the 
product’s public health impact. The HAS opin-
ion specifies whether the actual benefit is suffi-
cient to justify reimbursement.
The •	 therapeutic	improvement in actual benefit, 
based on a relative effectiveness assessment, 
provided by the product. The clinical improve-
ment brought by the product, relative to existing 
therapies, is assessed on a five-level scale, rang-
ing from level I (major improvement) to level V 
(no improvement).
The opinion is sometimes accompanied by a 
request for post-launch studies, in order to provide 
useful data at the time of reassessment regarding con-
ditions of use or reasons for discontinuation. The final 
opinion is sent to decision-makers (Ministry for Health 
and Social Security, union of sickness funds).
To promote timeliness, HAS has defined several 
different types of assessment procedures. There is a 
choice between simplified versus full-scale assess-
ments, depending on the complexity of the topic. A 
fast-track procedure has also been implemented for 
innovative drugs. The STA process must be performed 
within timelines set by law. For medical devices and 
drugs, the target is 90 days from the initial application 
to the final opinion; for procedures, the timeline is 180 
days. In 2007, the mean delay was 73 days for drugs 
and 142 days for medical devices.
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For MTA, the HAS methodology follows inter-
national standards for technology assessment. For a 
selected topic, several steps are followed:
A scoping process involving the main stake-•	
holders, to define relevant aspects to be 
assessed. In general, clinical effectiveness, 
harms, and conditions of use are systematically 
assessed. According to the topic, economical, 
ethical, legal, and societal dimensions may also 
be assessed.
Definition of the most appropriate method for •	
the assessment of the selected aspects.
Critical review of available evidence (selection •	
of published data according to the level and 
quality of evidence).
Consultation with experts, using working group •	
meetings, formalized experts’ consensus, or the 
Delphi method (a systematic, interactive 
forecasting method that relies on a panel of 
independent experts).
Production of a first version of the assessment •	
report, peer review when necessary, and 
appraisal and final opinion by the relevant spe-
cialist committee.
Validation by the HAS board and publication on •	
the HAS Web site.
Economic Evaluation
Although a small number of economic analyses have 
been conducted in the past by HAS and one of its pre-
cursor agencies, legislation in 2008 entrusted HAS 
with the explicit mission of issuing “recommendations 
and medico-economic opinions on the most effective 
strategies of care, prescription, and disease manage-
ment.” Economic evaluation has thus been declared as 
one of the tools to be used by HAS in aiding public 
decision-making. This applies to health actions and 
program evaluation, as well as to reimbursement deci-
sions for health products.
The economic analyses conducted by HAS help 
underline the opportunity costs associated with reim-
bursement decisions and contribute toward making the 
use of reimbursable goods and services more efficient. 
Over time, economic evaluation should also become 
useful to medical professionals in their attempt to pre-
scribe health care resources more efficiently.
Three types of economic assessments are  
produced:
When strategies are identical both in terms of 1. 
medical efficacy and tolerance, the least expen-
sive strategy is recommended. The economic 
calculation may involve a simple comparison of 
prices of a daily treatment—for example, the 
treatment of arterial hypertension with angios-
tensin-converting enzyme (ACE) inhibitors ver-
sus angiotensin II receptor antagonists (ARBs). 
Or it may involve modeling of the costs of an 
entire disease management pathway.
When a difference in efficacy or patient toler-2. 
ance is identified, the economic evaluation 
takes into account both outcomes and costs, 
thus valuing the cost of the efficacy increase. 
Examples include published work on the role of 
immunological tests in screening for colorectal 
cancer and several studies currently under way, 
including assessments of statins, of noninvasive 
measures of hepatic fibrosis, and of the role of 
systems of self-measurement in the follow-up of 
patients treated with the anticoagulant VKA. 
HAS could also consider requesting additional 
economic data when post-marketing studies are 
undertaken.
For a limited number of topics, a full-scale 3. 
MTA is carried out in order to measure the 
added value to the community of health strate-
gies, products, and technologies. An example of 
such a topic is the use of human growth hor-
mones in children. This global approach will 
strive to document, beyond economic aspects, 
other considerations regarding organizational, 
social or ethical aspects.
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The choice of intervention level is made on the 
basis of a systematic list of criteria.
Assessments are conducted by a new depart-
ment of HAS, the economic evaluation and public 
health service, either internally or using outside 
experts. The intention is to develop a network of col-
laborating research centers over time. Work is over-
seen by a new interdisciplinary committee for eco-
nomic and public health evaluation, which offers guid-
ance during the scoping phase, examines potential 
conflicts of interest, and evaluates the scientific quality 
and ethics of completed work. The 25-member com-
mittee includes health professionals, patients’ represen-
tatives, and experts representing eight different disci-
plines (economics, public health, management, admin-
istration, epidemiology, pharmacology, sociology and 
philosophy). HAS distinguishes the clinical evaluation 
of services from the economic evaluation phase, while 
ensuring they are complementary. The clinical evalua-
tion remains the responsibility of the specialist com-
mittees for drugs, medical devices, professional proce-
dures, and professional guidelines.
HAS made the decision to respond promptly to 
its new mission, rather than wait for methods to be 
fully stabilized. It will pragmatically develop its own 
methods while exchanging with its foreign counter-
parts. Methodological guides will be made available 
progressively. Transparency of methods and opinions 
is ensured by consultation of the stakeholders: payers, 
patients, health care professionals and representatives 
from industry.
As a general rule, economic assessments will be 
included in MTAs rather than in STAs. Consequently, 
pricing decisions for new technologies on the basis of 
STAs will not be modified by the new HAS activity. 
Expected impact on prices will be mainly the results of 
reexamination of a class of treatments through MTAs. 
The HAS purpose in producing economic assessments 
is also to assist health insurance funds in their effort to 
encourage more efficient use of health care resources.
Appeal
All guidance reports issued by HAS are submitted to 
product sponsors before a final version is issued. 
Companies have the right to appeal by sending, within 
eight days, either written comments or a request for a 
hearing to the committee that produced the guidance. 
Opinions may be changed after consideration of the 
arguments raised by the company/companies. After a 
decision has been made on the basis of HAS guidance, 
companies may appeal to the supreme administrative 
court (Conseil d’Etat).
Conflict of Interest Policies
To carry out assessments, HAS recruits experts and 
uses an internal guideline for the management of con-
flicts of interest. A transparent process has been put in 
place to deal with this issue, with a screening phase of 
experts’ CVs, rejection of experts with major conflicts 
of interest, announcement of potential conflicts during 
committees’ meetings, and disclosures of these conflicts 
in the minutes of the committee meetings. All declara-
tions of interests (internal and external experts) are 
made public on the HAS Web site. To prevent conflicts 
of interest and comply with ethical principles, an inde-
pendent group of external experts on “ethics and inde-
pendent expert opinion” was created in 2007. An ethical 
charter has been prepared and will be issued shortly.
Consultation with Stakeholders
Beyond regular consultation with stakeholders both 
during the annual work program definition and the 
hearings for specialist committees, HAS has recently 
experimented with external public consultation through 
its Web site on two topics: chronic disease manage-
ment and task delegation between health professionals.
Dealing with Uncertainty
When issuing an opinion on a new technology, HAS 
may request that post-coverage observational studies 
be carried out. Questions may relate to conditions of 
use of products or, when justified by residual clinical 
uncertainty, to their effectiveness under real-life condi-
tions, reasons for treatment discontinuation, or safety 
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issues. (In the case of safety questions, the study’s 
objectives are shared with the French drug regulatory 
agency in the context of risk management plans.)
Access to Innovation
HAS has developed various actions to improve access 
to innovation in terms of timeliness and quality of 
evaluation. HAS can use fast-track procedures, priori-
tize the assessment of high-value technologies, and 
recommend conditional coverage with a requirement 
for prospective data collection, within well-defined 
conditions of use, performed by well-identified teams 
with specific skills in a selected number of centers. 
This mechanism enables decision-makers to closely 
monitor innovative technologies and to manage their 
diffusion. It ensures, at the same time, the generation 
of additional evidence to further reduce uncertainty.
For procedures, there is a well-defined regula-
tory framework, within which HAS can specify the 
type of data that should be collected while a temporary 
conditional coverage is granted. However, implemen-
tation of this mechanism has so far been poor, mainly 
because of a lack of financing sources for clinical 
studies and a lack of linkage with research programs. 
This framework will probably be extended to cover 
medical devices, with some of the operational issues 
addressed, starting in 2009.
For drugs, no comparable formal “research 
only” framework exists. However, drugs are reassessed 
within five years of their approval at the latest, and 
often sooner if significant new information becomes 
available to HAS. For innovative drugs that are autho-
rized at an early stage of development, clinical trials 
are still ongoing at the time the drug is licensed, and 
the company has to submit its results to HAS as soon 
as they are available, leading to a reassessment of  
the product.
IMPACT ON POLICY AND PRACTICE: SELECTED 
CASE STUDIES AND OVERALL TRENDS
The impact of HTA products on the health care system 
is difficult to measure. Yet there are many examples of 
HTA reports that have had a real impact on French 
health policy, especially in the field of public health.
The majority of the decisions made by the 
Ministry of Health and sickness funds reflect the STA 
opinions delivered by HAS specialist committees dedi-
cated to drug, device, and procedure assessments. It is 
estimated that more than 95 percent of HAS positive 
opinions regarding the reimbursement status of a new 
technology are followed by decisions to reimburse that 
technology. Negative opinions are, in the case of new 
technologies, followed in almost all cases. One excep-
tion was the response to HAS recommendations 
regarding the delisting of existing drugs.
From 1999 to 2001, all medicines qualifying for 
reimbursement were reassessed, at the request of the 
Ministry for Health and Social Security. Over that 
period, the HAS Transparency Committee examined 
4,490 medicines and concluded that 835 of them 
showed insufficient benefit to warrant reimbursement. 
The reimbursement rates for those medicines with 
insufficient benefit were first reduced. It was then 
decided to update the reassessment. The products were 
reassessed by the Transparency Committee from 2003 
to 2006. Altogether, HAS proposed the delisting of 
370 drugs, of which 322 were delisted by decisions of 
the Minister for Health and Social Security. The 
Minister decided to retain 48 drugs, mainly vasodila-
tors used to treat “cerebral insufficiency” in the elderly 
population, on the positive list. This mixed experience 
reflects, on the one hand, the high impact HAS opin-
ions have on decision-makers; at the same time, it can 
be seen as reflecting the independence of HAS within 
the policy process.
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